Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
Deloitte
Express Scripts
Teva
Cerilliant
Queensland Health
Julphar
Moodys

Generated: September 19, 2018

DrugPatentWatch Database Preview

ZOMIG-ZMT Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Zomig-zmt patents expire, and what generic alternatives are available?

Zomig-zmt is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

Drug patent expirations by year for ZOMIG-ZMT
Synonyms for ZOMIG-ZMT
(4S)-4-((3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-5-YL)METHYL)-2-OXAZOLIDINONE
(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
(4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
(4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]oxazolidin-2-one
(S) -N,N-Dimethyl-2- [5- (2-oxo-1,3-oxazolidin-4-ylmethyl) -1H -indol-3-yl]ethylamine
(S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
(S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one
(S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone
(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
(S)-4-(3-[2-(DIMETHYLAMINO)ETHYL]-5-INDOLYLMETHYL)OXAZOLIDIN-2-ONE
(S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone
(S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one
(S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H -indol-3-yl]ethylamine
(S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine
139264-17-8
2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)-
2FS66TH3YW
311C90
4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
64Z178
A-2479
AB00698244_06
AB00698244-05
AB07628
AB2000194
AC1L1U2E
ACT04392
AK-47834
AKOS015850706
AN-5272
AscoTop
AscoTop (TN)
AscoTopand
AT-3239
B2261
BC206232
BDBM50033383
BIDD:GT0040
BW-311C90
C07218
C16H21N3O2
CAS-139264-17-8
CCG-38993
CHEBI:10124
CHEMBL1185
CPD000449310
CS-2179
D00415
D0NG7O
DB00315
DSSTox_CID_25933
DSSTox_GSID_45933
DSSTox_RID_81232
DTXSID8045933
Flezol
FT-0631159
GTPL60
HMS1922B04
HMS2052K17
HMS2093O14
HMS2235I22
HY-B0229
J-007257
J10141
KB-62428
KS-00000HAJ
KS-5072
LS-100559
MFCD00871503
MLS000758208
MLS001424172
MolPort-003-666-626
NC00382
NCGC00095155-01
NCGC00263884-02
NCGC00263884-03
NSC-760383
NSC760383
Pharmakon1600-01505281
Rapimelt
s1649
SAM001246841
SAM001247064
SBI-0206762.P001
SC-17326
SCHEMBL33336
SMR000449310
SPBio_000656
SPECTRUM1505281
Spectrum2_000728
SR-05000001693
SR-05000001693-1
ST2407794
Tox21_111455
Tox21_111455_1
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
UNII-2FS66TH3YW
ZINC15515
zipton
ZMT
zolmitriptan
Zolmitriptan (JAN/USAN/INN)
Zolmitriptan (Zomig)
Zolmitriptan [USAN]
Zolmitriptan RapidFilm
Zolmitriptan, >=98% (HPLC)
Zolmitriptan, United States Pharmacopeia (USP) Reference Standard
zolmitriptane
zolmitriptanum
Zomig
Zomig (TN)
Zomig Nasal Spray
Zomig ZMT
Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan
Zomig;Zomigon;AscoTopand;Zomigoro
Zomigon
Zomigon (TN)
Zomigoro
Zomigoro (TN)
zominat

US Patents and Regulatory Information for ZOMIG-ZMT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-001 Feb 13, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-002 Sep 17, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ZOMIG-ZMT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-001 Feb 13, 2001 ➤ Sign Up ➤ Sign Up
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-002 Sep 17, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
Deloitte
Express Scripts
Teva
Cerilliant
Queensland Health
Julphar
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.